MCID: DBT026
MIFTS: 89

Diabetes Mellitus, Noninsulin-Dependent

Categories: Genetic diseases, Endocrine diseases, Metabolic diseases

Aliases & Classifications for Diabetes Mellitus, Noninsulin-Dependent

MalaCards integrated aliases for Diabetes Mellitus, Noninsulin-Dependent:

Name: Diabetes Mellitus, Noninsulin-Dependent 53 13 37
Niddm 53 12 24 71 51
Diabetes Mellitus, Non-Insulin-Dependent 53 24 71 69
Type 2 Diabetes Mellitus 37 12 24 14
Insulin Resistance 53 28 51 69
Noninsulin-Dependent Diabetes Mellitus 53 24 71
Diabetes Mellitus, Type 2 53 24 41
Diabetes Mellitus Type 2 72 71 28
Maturity-Onset Diabetes 53 24 71
T2d 53 24 71
Insulin Resistance, Severe, Digenic 53 13
Adult-Onset Diabetes Mellitus 24 71
Diabetes Mellitus, Type Ii 53 24
Type Ii Diabetes Mellitus 12 36
Type 2 Diabetes 24 59
Diabetes Mellitus, Non-Insulin-Dependent, Susceptibility to 53
Hypertension, Insulin Resistance-Related, Susceptibility to 53
Diabetes Mellitus, Noninsulin-Dependent, Susceptibility to 53
Diabetes Mellitus, Noninsulin-Dependent, Association with 53
Diabetes Mellitus, Noninsulin-Dependent, Late Onset 53
Diabetes Mellitus, Type Ii, Susceptibility to 53
Diabetes Mellitus, Type 2, Susceptibility to 53
Diabetes Mellitus, Noninsulin-Dependent, 2 53
Hypertension, Insulin Resistance-Related 53
Non-Insulin-Dependent Diabetes Mellitus 12
Insulin Resistance, Susceptibility to 53
Diabetes, Type 2, Susceptibility to 53
Maturity-Onset Diabetes Mellitus 24
Diabetes Mellitus, Type Ii; T2d 53
Diabetes Mellitus, Adult-Onset 24
Diabetes Mellitus Type Ii 71
Adult-Onset Diabetes 24
Diabetes Mellitus 69
Diabetes, Type 2 53
Diabetes Type 2 40
Aodm 24

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
diabetes mellitus, noninsulin-dependent:
Inheritance autosomal dominant inheritance
Onset and clinical course late onset


Classifications:



Summaries for Diabetes Mellitus, Noninsulin-Dependent

MedlinePlus : 40 Diabetes means your blood glucose, or blood sugar, levels are too high. With type 2 diabetes, the more common type, your body does not make or use insulin well. Insulin is a hormone that helps glucose get into your cells to give them energy. Without insulin, too much glucose stays in your blood. Over time, high blood glucose can lead to serious problems with your heart, eyes, kidneys, nerves, and gums and teeth. You have a higher risk of type 2 diabetes if you are older, have obesity, have a family history of diabetes, or do not exercise. Having prediabetes also increases your risk. Prediabetes means that your blood sugar is higher than normal but not high enough to be called diabetes. If you are at risk for type 2 diabetes, you may be able to delay or prevent developing it by making some lifestyle changes. The symptoms of type 2 diabetes appear slowly. Some people do not notice symptoms at all. The symptoms can include Being very thirsty Urinating often Feeling very hungry or tired Losing weight without trying Having sores that heal slowly Having blurry eyesight Blood tests can show if you have diabetes. One type of test, the A1C, can also check on how you are managing your diabetes. Many people can manage their diabetes through healthy eating, physical activity, and blood glucose testing. Some people also need to take diabetes medicines. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Mellitus, Noninsulin-Dependent, also known as niddm, is related to diabetes mellitus and body mass index quantitative trait locus 11, and has symptoms including type ii diabetes mellitus, insulin resistance and symptoms. An important gene associated with Diabetes Mellitus, Noninsulin-Dependent is IRS1 (Insulin Receptor Substrate 1), and among its related pathways/superpathways are Cell cycle and p53 signaling pathway. The drugs Linagliptin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include Pancreas and Adipose, and related phenotypes are Decreased viability in esophageal squamous lineage and shRNA abundance <= 50%

UniProtKB/Swiss-Prot : 71 Diabetes mellitus, non-insulin-dependent: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

Genetics Home Reference : 24 Type 2 diabetes is a disorder characterized by abnormally high blood sugar levels. In this form of diabetes, the body stops using and making insulin properly. Insulin is a hormone produced in the pancreas that helps regulate blood sugar levels. Specifically, insulin controls how much glucose (a type of sugar) is passed from the blood into cells, where it is used as an energy source. When blood sugar levels are high (such as after a meal), the pancreas releases insulin to move the excess glucose into cells, which reduces the amount of glucose in the blood.

Disease Ontology : 12 A diabetes mellitus that involves high blood glucose resulting from cells fail to use insulin properly.

PubMed Health : 59
About type 2 diabetes: Type 2 diabetes (diabetes mellitus) is a metabolic disease that causes sugar to build up in the blood stream. The severity of diabetes can vary quite a bit: Some people only have to make minor changes to their lifestyle after they are diagnosed. Just losing a little weight and getting a bit more exercise may be enough for them to manage their diabetes. Other people who have type 2 diabetes need long-term treatment that involves taking tablets or insulin. It is then especially important for them to have a good understanding of their disease and know what they can do to stay healthy.There are two main types of diabetes. Type 1 diabetes usually develops in childhood or teenage years. This disease is a result of damage to the pancreas that leaves it producing either very little insulin or none at all.Things are different in type 2 diabetes, where insulin is made by the pancreas but the body’s cells gradually lose the ability to absorb and use the insulin. In the past, type 2 diabetes was often referred to as “adult-onset” diabetes because it is commonly diagnosed later in life. Type 2 diabetes is much more common than type 1 diabetes. About 90% of people who have diabetes have type 2 diabetes.

Wikipedia : 72 Diabetes mellitus... more...

Description from OMIM: 125853

Related Diseases for Diabetes Mellitus, Noninsulin-Dependent

Diseases in the Diabetes Mellitus, Noninsulin-Dependent family:

Diabetes Mellitus, Noninsulin-Dependent, 1 Diabetes Mellitus, Noninsulin-Dependent, 2
Diabetes Mellitus, Noninsulin-Dependent, 3 Diabetes Mellitus, Noninsulin-Dependent, 4
Diabetes Mellitus, Noninsulin-Dependent, 5

Diseases related to Diabetes Mellitus, Noninsulin-Dependent via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus 32.8 ABCC8 AKT2 ENPP1 GCGR GCK HNF1A
2 body mass index quantitative trait locus 11 32.1 ENPP1 GCK INSR IRS1 RETN SLC2A2
3 hyperglycemia 31.4 ABCC8 GCGR GCK HNF1A INSR IRS1
4 maturity-onset diabetes of the young 31.4 ABCC8 GCK HNF1A HNF1B HNF4A IRS1
5 glucose intolerance 31.0 GCK INSR IRS1 RETN
6 gestational diabetes 31.0 GCK HNF1A INSR IRS1 KCNJ11 RETN
7 hyperinsulinism 30.9 ABCC8 GCK HNF4A INSR KCNJ11
8 hypoglycemia 30.9 ABCC8 AKT2 GCK INSR KCNJ11
9 insulin-like growth factor i 30.4 AKT2 INSR IRS1
10 insulin-resistant acanthosis nigricans, type a 12.6
11 diabetes mellitus, noninsulin-dependent, 1 12.5
12 diabetes mellitus, noninsulin-dependent, 2 12.5
13 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 12.5
14 diabetes mellitus, noninsulin-dependent, 4 12.5
15 diabetes mellitus, noninsulin-dependent, 5 12.5
16 diabetes mellitus, noninsulin-dependent, 3 12.4
17 diabetes mellitus, insulin-resistant, with acanthosis nigricans 12.4
18 insulin-resistance type b 12.4
19 intrauterine growth restriction-short stature-early adult-onset diabetes syndrome 12.2
20 hair-an syndrome 12.0
21 pseudoacromegaly with severe insulin resistance 12.0
22 insr-related severe syndromic insulin resistance 12.0
23 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 12.0
24 microcephalic primordial dwarfism-insulin resistance syndrome 12.0
25 short fifth metacarpals-insulin resistance syndrome 12.0
26 short syndrome 11.8
27 lipodystrophy, familial partial, type 3 11.3
28 maturity-onset diabetes of the young, type 2 11.1
29 diabetes and deafness, maternally inherited 11.1
30 glucose metabolism disease 11.1 ABCC8 GCK IRS1 KCNJ11 RETN SLC2A2
31 neonatal diabetes mellitus 11.0 ABCC8 GCK HNF1B KCNJ11 NEUROD1 SLC2A2
32 monogenic diabetes 11.0 ABCC8 GCK HNF1A HNF1B HNF4A KCNJ11
33 alstrom syndrome 11.0
34 laron syndrome 11.0
35 acquired metabolic disease 11.0 GCK IRS1 KCNJ11 RETN SLC2A2
36 hyperinsulinemic hypoglycemia 11.0 ABCC8 GCK HNF4A INSR KCNJ11
37 insulinoma 11.0 ABCC8 GCK NEUROD1 SLC2A2 WFS1
38 fasting plasma glucose level quantitative trait locus 1 11.0
39 diabetes mellitus, insulin-dependent 11.0 GCK HNF1A NEUROD1 PAX4 WFS1
40 endocrine pancreas disease 10.9 ABCC8 GCK IRS1 KCNJ11
41 munchausen by proxy 10.9 ABCC8 GCK KCNJ11
42 factitious disorder 10.9 ABCC8 GCK KCNJ11
43 hyperinsulinemic hypoglycemia, familial, 2 10.9 ABCC8 HNF4A KCNJ11
44 lutheran suppressor, x-linked 10.9 INSR IRS1 RETN
45 pancreatic agenesis 10.8 ABCC8 GCK KCNJ11
46 pancreatic cancer 10.8
47 diabetes mellitus, transient neonatal, 3 10.8
48 hyperinsulinemic hypoglycemia, familial, 3 10.8 ABCC8 GCK
49 maturity-onset diabetes of the young, type 6 10.8 HNF1A NEUROD1
50 diabetes mellitus, permanent neonatal 10.8 ABCC8 GCK KCNJ11

Graphical network of the top 20 diseases related to Diabetes Mellitus, Noninsulin-Dependent:



Diseases related to Diabetes Mellitus, Noninsulin-Dependent

Symptoms & Phenotypes for Diabetes Mellitus, Noninsulin-Dependent

Symptoms via clinical synopsis from OMIM:

53
Endo:
noninsulin-dependent diabetes mellitus

Lab:
insulin resistance
decreased glucose disposal

Misc:
late onset


Clinical features from OMIM:

125853

Human phenotypes related to Diabetes Mellitus, Noninsulin-Dependent:

31
# Description HPO Frequency HPO Source Accession
1 type ii diabetes mellitus 31 HP:0005978
2 insulin resistance 31 HP:0000855

UMLS symptoms related to Diabetes Mellitus, Noninsulin-Dependent:


symptoms, equilibration disorder, tremor, angina pectoris

GenomeRNAi Phenotypes related to Diabetes Mellitus, Noninsulin-Dependent according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.65 ABCC8 GCGR HNF1B HNF4A INSR MAPK8IP1
2 shRNA abundance <= 50% GR00343-S 9.32 ENPP1 GCGR GCK GPD2 HNF1A HNF4A

MGI Mouse Phenotypes related to Diabetes Mellitus, Noninsulin-Dependent:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.28 GPD2 HNF1A AKT2 ENPP1 GCGR GCK
2 endocrine/exocrine gland MP:0005379 10.27 ABCC8 AKT2 GCGR GCK GPD2 HNF1A
3 homeostasis/metabolism MP:0005376 10.26 ABCC8 AKT2 ENPP1 GCGR GCK GPD2
4 cellular MP:0005384 10.14 MAPK8IP1 NEUROD1 AKT2 ENPP1 GCGR HNF1A
5 adipose tissue MP:0005375 10.13 AKT2 ENPP1 GCGR GPD2 HNF1A INSR
6 liver/biliary system MP:0005370 10 HNF1B HNF4A INSR IRS1 MAPK8IP1 RETN
7 mortality/aging MP:0010768 9.86 GPD2 HNF1A HNF1B HNF4A INSR IRS1
8 muscle MP:0005369 9.28 AKT2 ENPP1 HNF1A HNF1B INSR IRS1

Drugs & Therapeutics for Diabetes Mellitus, Noninsulin-Dependent

PubMedHealth treatment related to Diabetes Mellitus, Noninsulin-Dependent: 59

A number of factors influence which treatment approach for type 2 diabetes is most suitable: They include age, general physical condition, other health problems, life circumstances and personal goals.Sometimes just changing your lifestyle can have a positive effect: Losing weight and getting more exercise can make insulin more effective and lower blood sugar levels. Quitting smoking helps to reduce the risk of cardiovascular disease. Making these kinds of changes is sometimes enough to manage the condition and associated risks.If very overweight (obese) people find it hard to lose weight, surgical approaches such as stomach stapling may be an option.Some people depend on medication to regulate their blood sugar levels. The medication options include taking tablets, injecting insulin or medication called incretin mimetics (hormone-like substances that are designed to increase the body's insulin production). It's also possible to combine tablets and injections. The most common medications used to treat type 2 diabetes (antidiabetic drugs) are metformin and sulfonylureas. Newer antidiabetic drugs are also available – but there are still many unanswered questions about their effects.Depending on what other symptoms and illnesses a person has, different kinds of medication can be used to lower particular risks. For example, many people who have type 2 diabetes also have high blood pressure.The main medications that can lower the risk of cardiovascular diseaselower blood pressure (antihypertensives),prevent blood clotting (ASA, the drug in medications like Aspirin), orreduce cholesterol levels (statins).

Drugs for Diabetes Mellitus, Noninsulin-Dependent (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 956)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 668270-12-0 10096344
2
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 4091 14219
3
Voglibose Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83480-29-9 444020
4
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 160337-95-1
5
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 7440-66-6 32051 23994
6
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
7
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 141758-74-9 15991534
8
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1 169148-63-4 5311023
9
Glipizide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 29094-61-9 3478
10
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 361442-04-8 11243969
11
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 56180-94-0 441184
12
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
13
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1 204656-20-2 44147092
14
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1 133107-64-9
15
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 116094-23-6 16132418
16
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1 93479-97-1 3476
17
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 3 128-13-2 31401
18
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
19
Insulin-glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1 207748-29-6
20
Clopidogrel Approved Phase 4,Phase 2 120202-66-6, 113665-84-2 60606
21
Ramipril Approved Phase 4,Phase 3,Early Phase 1 87333-19-5 5362129
22
Ticlopidine Approved Phase 4,Phase 2 55142-85-3 5472
23
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
24
Fluvastatin Approved Phase 4,Phase 3 93957-54-1 1548972
25
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1 137862-53-4 60846
26
Alogliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 850649-61-5 11450633
27
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
28
Canagliflozin Approved Phase 4,Phase 3,Phase 2,Phase 1 842133-18-0
29
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 274901-16-5 6918537
30
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
31
Gliclazide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21187-98-4 3475
32
Amlodipine Approved Phase 4,Phase 3,Phase 1 88150-42-9 2162
33
Atenolol Approved Phase 4 29122-68-7 2249
34
Clonidine Approved Phase 4,Phase 3 4205-90-7 2803
35
Doxazosin Approved Phase 4 74191-85-8 3157
36
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 1 54-31-9 3440
37
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-93-5 3639
38
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 138402-11-6 3749
39
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
40
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2 75847-73-3 40466924 5362032
41
Enalaprilat Approved Phase 4,Phase 3,Phase 2 76420-72-9 6917719
42
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
43
Nitric Oxide Approved Phase 4,Phase 2,Phase 3 10102-43-9 145068
44
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2 135062-02-1 65981
45
Glyburide Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 10238-21-8 3488
46
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
47
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
48
Curcumin Approved, Investigational Phase 4,Phase 2,Phase 3 458-37-7 969516
49
Ezetimibe Approved Phase 4,Phase 3,Phase 2 163222-33-1 150311
50
Cilostazol Approved, Investigational Phase 4,Phase 3 73963-72-1 2754

Interventional clinical trials:

(show top 50) (show all 7092)

# Name Status NCT ID Phase Drugs
1 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
2 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
3 Continuous Glucose Monitoring in Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
4 The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient Unknown status NCT02261545 Phase 4
5 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
6 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
7 Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes Unknown status NCT00991055 Phase 4 Pioglitazone
8 Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes Unknown status NCT01435980 Phase 4 Exenatide
9 Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes Unknown status NCT01281605 Phase 4
10 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
11 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4 Glipizide;Acarbose
12 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
13 Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes Unknown status NCT02344186 Phase 4 Liraglutide
14 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
15 Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus Unknown status NCT00298844 Phase 4
16 Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes Unknown status NCT02449603 Phase 4 Exenatide;Biphasic insulin Aspart 30
17 Evaluating the Effect of a Diabetes Health Coach in Individuals With Type 2 Diabetes Unknown status NCT02128815 Phase 4
18 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices Unknown status NCT02361489 Phase 4
19 Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes Unknown status NCT02605772 Phase 4 Acarbose;Metformin;Saxagliptin
20 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4 dapagliflozin;glimpiride
21 Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes Unknown status NCT00747409 Phase 4 insulin aspart and detemir (NovoRapid, Levemir);human regular insulin and NPH insulin (Actrapid, Protaphne)
22 Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients Unknown status NCT00399204 Phase 4 Pioglitazone vs Metformin
23 The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion Unknown status NCT02406443 Phase 4 Sitaglitpin
24 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
25 the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes Unknown status NCT01876563 Phase 4
26 Thyroid Study Type 2 Diabetes Mellitus (T2DM) Unknown status NCT01379170 Phase 4 Euthyrox (levothyroxine)
27 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
28 The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics Unknown status NCT01478776 Phase 4
29 A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes Unknown status NCT02606617 Phase 4 Mosapride;Placebo
30 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
31 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
32 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
33 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
34 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
35 Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
36 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride
37 Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy Unknown status NCT02129985 Phase 4 Exenatide;Metformin
38 Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study) Unknown status NCT02512523 Phase 4 Teneligliptin;Sitagliptin
39 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
40 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
41 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
42 Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes Unknown status NCT01978405 Phase 4 Alpha lipoic acid
43 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
44 the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin Unknown status NCT02438397 Phase 4 premix insulin;metformin;Acarbose
45 Safety and Efficacy of Saxagliptin vs.Glimepiride as Add-on Therapy in T2DM Patients With Metformin Monotherapytients Unknown status NCT02280486 Phase 4 Saxagliptin;Glimepiride
46 Glycemic Durability After Metformin Failure Unknown status NCT02142309 Phase 4 Glimepiride;Vildagliptin;Pioglitazone;Canagliflozin
47 Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
48 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
49 Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells Unknown status NCT00523393 Phase 4 Insulin Glargin;Human Insulin
50 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo

Search NIH Clinical Center for Diabetes Mellitus, Noninsulin-Dependent

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: diabetes mellitus, type 2

Genetic Tests for Diabetes Mellitus, Noninsulin-Dependent

Genetic tests related to Diabetes Mellitus, Noninsulin-Dependent:

# Genetic test Affiliating Genes
1 Diabetes Mellitus Type 2 28 ABCC8 AKT2 CDKAL1 ENPP1 GCGR GCK GPD2 HMGA1 HNF1A HNF1B HNF4A IGF2BP2 IRS1 IRS2 KCNJ11 LIPC MAPK8IP1 MTNR1B NEUROD1 PAX4 PDX1 PPARG PPP1R3A PTPN1 RETN SLC2A2 SLC30A8 TCF7L2 WFS1
2 Insulin Resistance 28

Anatomical Context for Diabetes Mellitus, Noninsulin-Dependent

MalaCards organs/tissues related to Diabetes Mellitus, Noninsulin-Dependent:

38
Heart, Endothelial, Kidney, Liver, Testes, Bone, Ovary
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Diabetes Mellitus, Noninsulin-Dependent:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Mature Beta Cells Potential therapeutic candidate, affected by disease
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Diabetes Mellitus, Noninsulin-Dependent

Articles related to Diabetes Mellitus, Noninsulin-Dependent:

(show top 50) (show all 541)
# Title Authors Year
1
Prevalence and severity of periodontal disease in type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus) patients in Bangalore city: An epidemiological study. ( 23633768 )
2013
2
Rhus coriaria ameliorates insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) rats. ( 24147364 )
2013
3
Genome-wide linkage and admixture mapping of type 2 diabetes in African American families from the American Diabetes Association GENNID (Genetics of NIDDM) Study Cohort. ( 18840782 )
2009
4
Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. ( 17924055 )
2008
5
Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. ( 17317762 )
2007
6
Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. ( 16804087 )
2006
7
Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial. ( 16838170 )
2006
8
The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. ( 15656877 )
2005
9
The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. ( 15734870 )
2005
10
Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. ( 15592662 )
2004
11
NIDDM: new once-daily intervention for type 2 diabetes mellitus: Diaprel MR. ( 15529633 )
2004
12
Serum leptin levels in female patients with NIDDM. ( 12689528 )
2003
13
[Distribution and significance of cSNP in KCNA7 gene as a novel NIDDM candidate gene in the population of northeast China]. ( 15639836 )
2003
14
No association between oxidative stress and IL-6 in NIDDM patients with nephropathy. ( 14748439 )
2003
15
[The influence of spontaneous posterior vitreous detachment in resolution of diabetic macular edema in NIDDM]. ( 15049255 )
2003
16
Association between Apo B signal peptide gene polymorphism and NIDDM. ( 12736910 )
2003
17
[24-hour arterial hypertension profile and heart rhythm variability in patients with arterial hypertension and NIDDM]. ( 12181808 )
2002
18
[Genetic polymorphism of pyruvate dehydrogenase kinase 4 (PDK4), paraoxonase 2 (PON2), and fatty acid binding protein 2 (FABP2) in the NIDDM population of Senegal]. ( 15776585 )
2002
19
Analysis of polymorphism of the GLUT2 promoter in NIDDM patients and its functional consequence to the promoter activity. ( 12017192 )
2002
20
Role of ANG II in coronary capillary angiogenesis at the insulin-resistant stage of a NIDDM rat model. ( 12234789 )
2002
21
Polymorphisms 1704G/T, 2184A/G, and 2245G/A in the rage gene are not associated with diabetic retinopathy in NIDDM: pilot study. ( 11884895 )
2002
22
Application of stable isotopic techniques in the prevention of degenerative diseases like obesity and NIDDM in developing societies. ( 12362790 )
2002
23
Oxidant and antioxidant systems in niddm patients: influence of vitamin E supplementation. ( 11678585 )
2001
24
[Gly40Ser mutation of glucagon receptor gene and NIDDM in Han nationality]. ( 12536714 )
2001
25
Molecular cloning of a novel member of the GLUT family of transporters, SLC2A10 (GLUT10), localized on chromosome 20q13.1: a candidate gene for NIDDM susceptibility. ( 11247674 )
2001
26
Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. ( 11457670 )
2001
27
Diabetic cataract of the musk shrew (Suncus murinus, Insectivora) exhibiting spontaneous non-insulin dependent diabetes mellitus (NIDDM). ( 11769547 )
2001
28
Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial. ( 11137328 )
2000
29
Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. ( 11426588 )
2000
30
Preserved tissue-type plasminogen activator release and endothelium-dependent vasodilation in postmenopausal women with NIDDM. ( 10989320 )
2000
31
Treatment of renovascular hypertension using stent implantation in an elderly patient with NIDDM. ( 10852164 )
2000
32
Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in Type 2 diabetic (NIDDM) patients. ( 10826511 )
2000
33
Identification of mutations in the hepatocyte nuclear factor-1alpha gene in Japanese subjects with early-onset NIDDM and functional analysis of the mutant proteins. ( 10078571 )
1999
34
Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM. ( 11221811 )
1999
35
Derangements of pyruvate dehydrogenase in circulating lymphocytes of NIDDM patients and their healthy offspring. ( 10475149 )
1999
36
Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. ( 10027935 )
1999
37
[Pathogenesis of impaired insulin secretion in NIDDM]. ( 10199129 )
1999
38
Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance. ( 10023638 )
1999
39
Plasma lipoprotein (a) levels in Turkish NIDDM patients with and without vascular diabetic complications. ( 10511896 )
1999
40
Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects. ( 10500310 )
1999
41
Diets high and low in glycemic index versus high monounsaturated fat diets: effects on glucose and lipid metabolism in NIDDM. ( 10403584 )
1999
42
[Insulin resistance and metabolic syndrome in first-degree relatives of patients with NIDDM]. ( 10207842 )
1999
43
[NIDDM susceptibility genes]. ( 10199131 )
1999
44
Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review). ( 10465670 )
1999
45
Platelet membrane fluidity in non-insulin-dependent diabetes mellitus (NIDDM) subjects, in subjects with vascular atherosclerotic disease (VAD) and in VAD subjects with NIDDM. ( 10456470 )
1999
46
Lack of association between the heparan sulfate proteoglycan gene polymorphism and diabetic nephropathy in Japanese NIDDM with proliferative diabetic retinopathy. ( 10586428 )
1999
47
Increased plasma oxidizability and decreased erythrocyte and plasma antioxidative capacity in patients with NIDDM. ( 10731349 )
1999
48
Relationship between angiotensinogen gene M235T variant with diabetic nephropathy in Chinese NIDDM. ( 11717948 )
1999
49
Z-4 allele upstream of the aldose reductase gene is associated with proliferative retinopathy in Japanese patients with NIDDM, and elevated luciferase gene transcription in vitro. ( 10579460 )
1999
50
Mutational analysis of the coding regions of the genes encoding protein kinase B-alpha and -beta, phosphoinositide-dependent protein kinase-1, phosphatase targeting to glycogen, protein phosphatase inhibitor-1, and glycogenin: lessons from a search for genetic variability of the insulin-stimulated glycogen synthesis pathway of skeletal muscle in NIDDM patients. ( 10334321 )
1999